Conference Description:

Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil’s TREM2 asset, Ventus’ NLRP3 inhibitor in phase 2a, and promising phase 3 BTKi readouts from Sanofi and Roche, the field is beginning to show encouraging signs of clinical viability in targeting neuroinflammation. Now the real race begins. Uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today’s successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease.

The 8th Neuroimmunology Drug Development Summit is the industry’s only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year’s expanded program goes deeper than ever into emerging glial biology (TREM2 and beyond), peripheral immune pathways, and the technologies redefining how we discover, validate, and measure neuroinflammatory targets.

Across three days, 50+ discovery, preclinical, and translational leaders from Biogen, Sanofi, Merck, Lundbeck, Vigil Neuroscience, Bristol Myers Squibbs and more will unite to share hyper-current insights on merging neuroinflammatory mechanisms, cutting-edge glial models and omics technologies accelerating target discovery, next-generation biomarkers enhancing translation, and early clinical signals from novel neuroimmune-targeting therapies.

Join the global neuroimmunology community this year and help define the future of immune-modulating therapies for the brain.

Tickets: https://go.evvnt.com/3395845-2?pid=154
Time: 9:00 AM - 5:00 PM

Prices:
Industry Pricing - Conference + Workshop Day: USD 4297.00,
Industry Pricing - Conference Only: USD 3099.00,
Academic Pricing - Conference + Workshop Day: USD 3697.00,
Academic Pricing - Conference Only: USD 2699.00,
Vendor Pricing - Conference + Workshop Day: USD 5197.00,
Vendor Pricing - Conference Only: USD 3799.00

Speakers: Agnes Cheong, Senior Scientist, Sanofi, Andrew Kaplan, Principal Scientist and Lab Head, Bristol Myers Squibb, Borislav Dejanovic, Senior Director, Translational Sciences and External Innovation, Vigil Neuroscience, a Sanofi Company, Dimitry Ofengeim, Head of Precision Neurology and Neuroinflammation, Sanofi, Ioannis-Alexandros Gampierakis, Postdoctoral Research Fellow, Inflammation and Immunology, Pfizer, Kevin Dines, Scientific Executive Director, Bristol Myers Squibb , Markus Kummer, Senior Principal Research Scientist, AbbVie, Rebecca Mathew, Senior Principal Scientist, Merck, Tarek Samad, Senior Vice President and Global Head, Research, Lundbeck, Christian Mirescu. Chief Scientific Officer, Monument Biosciences, Hella Kohlhof, Chief Scientific Officer, Immunic Therapeutics, Jagadeesh Rao, Principal Scientist, IGC PHARMA, Julia Kuhn, Associate Director - Target Discovery and Genomics, Alector , Niels Plath, Chief Scientific Officer, Muna Therapeutics, Paul Song, Chief Executive Officer, NKGen Biotech, Peter Flynn, President and Chief Executive Officer, Arialys Therapeutics, Ralph Minter, Chief Scientific Officer, Alchemab Therapeutics